Manuscripts and Publications

Filters: Keyword is Pre-Exposure Prophylaxis  [Clear All Filters]
2015
Gilbert ALewis, Knopf AS, J Fortenberry D, Hosek SG, Kapogiannis BG, Zimet GD.  2015.  Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research.. J Adolesc Health. 57(1):113-9.
Mullins TLKowalczy, Lally M, Zimet G, Kahn JA.  2015.  Clinician attitudes toward CDC interim pre-exposure prophylaxis (PrEP) guidance and operationalizing PrEP for adolescents.. AIDS Patient Care STDS. 29(4):193-203.
2016
Mullins TLKowalczy, Zimet G, Lally M, Kahn JA.  2016.  Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.. AIDS Patient Care STDS. 30(7):339-48.
2017
Reisner SL, Jadwin-Cakmak L, Hughto JMWhite, Martinez M, Salomon L, Harper GW.  2017.  Characterizing the HIV Prevention and Care Continua in a Sample of Transgender Youth in the U.S.. AIDS Behav. 21(12):3312-3327.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Mullins TLKowalczy, Zimet G, Lally M, Xu J, Thornton S, Kahn JA.  2017.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Knopf AS, Ott MA, Liu N, Kapogiannis BG, Zimet GD, J Fortenberry D, Hosek SG.  2017.  Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV.. J Adolesc Health. 61(6):747-754.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
2018
Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P et al..  2018.  Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.. Clin Infect Dis. 66(2):213-219.
Doll M, J Fortenberry D, Roseland D, McAuliff K, Wilson CM, Boyer CB.  2018.  Linking HIV-Negative Youth to Prevention Services in 12 U.S. Cities: Barriers and Facilitators to Implementing the HIV Prevention Continuum.. J Adolesc Health. 62(4):424-433.
Baker Z, Javanbakht M, Mierzwa S, Pavel C, Lally M, Zimet G, Gorbach P.  2018.  Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data.. AIDS Behav. 22(4):1174-1183.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
2019
Arrington-Sanders R, Wilson CM, Perumean-Chaney SE, Patki A, Hosek S.  2019.  Brief Report: Role of Sociobehavioral Factors in Subprotective TFV-DP Levels Among YMSM Enrolled in 2 PrEP Trials.. J Acquir Immune Defic Syndr. 80(2):160-165.
Sullivan PS, Mena L, Elopre L, Siegler AJ.  2019.  Implementation Strategies to Increase PrEP Uptake in the South.. Curr HIV/AIDS Rep. 16(4):259-269.
Naar S, Hudgens MG, Brookmeyer R, Carcone AIdalski, Chapman J, Chowdhury S, Ciaranello A, W Comulada S, Ghosh S, Horvath KJ et al..  2019.  Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions.. AIDS Patient Care STDS. 33(9):388-398.
K Amico R, Miller J, Balthazar C, Serrano PAlonso, Brothers J, Zollweg S, Hosek S.  2019.  Integrated Next Step Counseling (iNSC) for Sexual Health and PrEP Use Among Young Men Who Have Sex with Men: Implementation and Observations from ATN110/113.. AIDS Behav. 23(7):1812-1823.
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ.  2019.  Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
2020
Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG et al..  2020.  Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.. Clin Infect Dis. 70(4):687-691.
Sullivan PS, Mouhanna F, Mera R, Pembleton E, Castel AD, Jaggi C, Jones J, Kramer MR, McGuinness P, McCallister S et al..  2020.  Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.. Ann Epidemiol. 44:16-30.
Siegler AJ, C Mehta C, Mouhanna F, Giler RMera, Castel A, Pembleton E, Jaggi C, Jones J, Kramer MR, McGuinness P et al..  2020.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.. Ann Epidemiol. 45:24-31.e3.
Siegler AJ.  2020.  Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision.. Am J Public Health. 110(3):267-268.
Siegler AJ, Wiatrek S, Mouhanna F, K Amico R, Dominguez K, Jones J, Patel RR, Mena LA, Mayer KH.  2020.  Validation of the HIV Pre-exposure Prophylaxis Stigma Scale: Performance of Likert and Semantic Differential Scale Versions.. AIDS Behav. 24(9):2637-2649.
2021
Piper KN, Escoffery C, Sales JM, Sheth AN.  2021.  Models of HIV Pre-Exposure Prophylaxis Care Used in Title X Family Planning Clinics in the Southern U.S.. J Adolesc Health. 68(3):480-487.
Siegler AJ.  2021.  Needed: A Life Course Perspective on Maintaining Pre-exposure Prophylaxis Use.. Clin Infect Dis. 72(3):386-387.
Sales JM, Escoffery C, Hussen SA, Haddad LB, McCumber M, Kwiatkowski E, Filipowicz T, Sanchez M, Psioda MA, Sheth AN.  2021.  Pre-exposure Prophylaxis Implementation in Family Planning Services Across the Southern United States: Findings from a Survey Among Staff, Providers and Administrators Working in Title X-Funded Clinics.. AIDS Behav. 25(6):1901-1912.
A Rosengren L, Lelutiu-Weinberger C, E Woodhouse W, Sandanapitchai P, Hightow-Weidman LB.  2021.  A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men.. AIDS Behav. 25(7):2054-2070.
Saleska JLonderee, Lee S-J, Leibowitz A, Ocasio M, Swendeman D.  2021.  A Tale of Two Cities: Exploring the Role of Race/Ethnicity and Geographic Setting on PrEP Use Among Adolescent Cisgender MSM.. AIDS Behav. 25(1):139-147.